The association between inflammatory biomarkers and statin use among patients with head and neck squamous cell carcinoma.
HPV
biomarkers
epidemiology
head and neck cancer
inflammation
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
08
02
2022
received:
20
10
2021
accepted:
09
03
2022
pubmed:
27
3
2022
medline:
6
5
2022
entrez:
26
3
2022
Statut:
ppublish
Résumé
Tumor-infiltrating lymphocytes (TILs) and cytokines are associated with prognosis among patients with head and neck squamous cell carcinoma (HNSCC). Statins (cholesterol-lowering drugs) may improve HNSCC prognosis, particularly in human papillomavirus (HPV)-positive cases, but the mechanism remains unclear. Statin use was collected from medical records for HNSCC cases (2008-2014). TILs were counted in tumor tissue, and a total weighted score (TILws) was created. Cytokines were measured in blood. The associations between statins and biomarkers were estimated using logistic (biomarker categories: <median, ≥median) and linear regression models (log-transformed continuous biomarkers) adjusted for age, smoking, and comorbidities. We observed a positive association between statins and TILs among HPV-positive patients (TILws odds ratio [OR] = 2.80; 95% CI = 1.03-7.61), but no association among HPV-negative patients. We observed no association between statins and cytokines. Statins may influence TILs in HPV-positive patients. This may be the mechanism through which they improve prognosis in HPV-positive HNSCC patients.
Sections du résumé
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) and cytokines are associated with prognosis among patients with head and neck squamous cell carcinoma (HNSCC). Statins (cholesterol-lowering drugs) may improve HNSCC prognosis, particularly in human papillomavirus (HPV)-positive cases, but the mechanism remains unclear.
METHODS
Statin use was collected from medical records for HNSCC cases (2008-2014). TILs were counted in tumor tissue, and a total weighted score (TILws) was created. Cytokines were measured in blood. The associations between statins and biomarkers were estimated using logistic (biomarker categories: <median, ≥median) and linear regression models (log-transformed continuous biomarkers) adjusted for age, smoking, and comorbidities.
RESULTS
We observed a positive association between statins and TILs among HPV-positive patients (TILws odds ratio [OR] = 2.80; 95% CI = 1.03-7.61), but no association among HPV-negative patients. We observed no association between statins and cytokines.
CONCLUSIONS
Statins may influence TILs in HPV-positive patients. This may be the mechanism through which they improve prognosis in HPV-positive HNSCC patients.
Identifiants
pubmed: 35338544
doi: 10.1002/hed.27040
pmc: PMC9088158
mid: NIHMS1789198
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1393-1403Subventions
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA129102
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA129102
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA046592
Pays : United States
Informations de copyright
© 2022 The Authors. Head & Neck published by Wiley Periodicals LLC.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9
pubmed: 12117737
J Physiol Pharmacol. 2009 Dec;60(4):141-6
pubmed: 20065508
N Engl J Med. 2001 Dec 27;345(26):1890-900
pubmed: 11756581
Int J Cancer. 2020 Dec 15;:
pubmed: 33320960
J Clin Oncol. 2016 Dec;34(34):4132-4141
pubmed: 27863190
Head Neck. 2019 May;41(5):1193-1198
pubmed: 30809863
Oral Oncol. 2019 Mar;90:54-66
pubmed: 30846177
Int J Cancer. 2017 Mar 1;140(5):1068-1081
pubmed: 27859151
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Head Neck. 2022 Jun;44(6):1393-1403
pubmed: 35338544
JAMA Otolaryngol Head Neck Surg. 2019 Nov 01;145(11):1012-1019
pubmed: 31486841
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Exp Immunol. 2010 Aug;161(2):298-305
pubmed: 20491794
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
Head Neck. 2016 Dec;38(12):1810-1820
pubmed: 27432208
Surg Oncol Clin N Am. 2015 Jul;24(3):379-96
pubmed: 25979389
Nat Rev Cancer. 2005 Dec;5(12):930-42
pubmed: 16341084
Oncotarget. 2018 Nov 6;9(87):35752-35761
pubmed: 30515267
Head Neck. 2018 Aug;40(8):1697-1706
pubmed: 29934959
Int J Cancer. 2014 Jun 15;134(12):2755-63
pubmed: 23913554
Cancer Treat Rev. 2015 Jun;41(6):554-67
pubmed: 25890842
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
Cancer. 2008 Aug 15;113(4):750-7
pubmed: 18536030
Atherosclerosis. 2000 Feb;148(2):209-14
pubmed: 10657556
Cancer. 2014 Sep 1;120(17):2704-12
pubmed: 24830761
Atherosclerosis. 2004 Nov;177(1):161-6
pubmed: 15488879
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):170-178
pubmed: 30630091
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Immunol Today. 1998 Sep;19(9):414-21
pubmed: 9745205
Circulation. 2000 Jan 18;101(2):207-13
pubmed: 10637210
J Thromb Haemost. 2005 Aug;3(8):1618-27
pubmed: 16102027
Atherosclerosis. 2011 Nov;219(1):253-8
pubmed: 21855068
Int J Cancer. 2012 Jul 15;131(2):E74-85
pubmed: 22020783
Cells. 2019 Sep 10;8(9):
pubmed: 31510065
PLoS Med. 2008 Apr 8;5(4):e78
pubmed: 18399716